Analysis of the PrimoTinA-asthma (severe asthma) trials revealed that tiotropium improved peak FEV1(0–3h) by 102 mL (P<0.01) and 148 mL (P<0.001) versus placebo in patients with both high (>430 μg/L) and low (≤430 μg/L) baseline serum IgE, respectively. The gene discussed is IGHE; the disease is asthma.